HK1207856A1 - -吡啶酮化合物 - Google Patents

-吡啶酮化合物

Info

Publication number
HK1207856A1
HK1207856A1 HK15108355.5A HK15108355A HK1207856A1 HK 1207856 A1 HK1207856 A1 HK 1207856A1 HK 15108355 A HK15108355 A HK 15108355A HK 1207856 A1 HK1207856 A1 HK 1207856A1
Authority
HK
Hong Kong
Prior art keywords
pyridone compound
pyridone
compound
Prior art date
Application number
HK15108355.5A
Other languages
English (en)
Inventor
Shoichi Kuroda
Yudai Imai
Takanori Kawaguchi
Keiko Fusegi
Masahiro Bohno
Hajime Asanuma
Tomomichi Chonan
Nagaaki Sato
Souichi MONMA
Shigetada Sasako
Marie MIZUTANI
Shin Itoh
Takumi Okada
Hirofumi Ota
Seishi Ishiyama
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of HK1207856A1 publication Critical patent/HK1207856A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK15108355.5A 2012-11-13 2015-08-28 -吡啶酮化合物 HK1207856A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 ２－ピリドン化合物

Publications (1)

Publication Number Publication Date
HK1207856A1 true HK1207856A1 (zh) 2016-02-12

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108355.5A HK1207856A1 (zh) 2012-11-13 2015-08-28 -吡啶酮化合物

Country Status (26)

Country Link
US (1) US9695148B2 (zh)
EP (1) EP2921489B1 (zh)
JP (1) JP5963025B2 (zh)
KR (1) KR102160841B1 (zh)
CN (1) CN104768944B (zh)
AU (1) AU2013345930B2 (zh)
BR (1) BR112015010823A2 (zh)
CA (1) CA2891406C (zh)
DK (1) DK2921489T3 (zh)
ES (1) ES2641469T3 (zh)
HK (1) HK1207856A1 (zh)
HU (1) HUE034557T2 (zh)
IL (1) IL238701B (zh)
IN (1) IN2015DN03869A (zh)
MX (1) MX361479B (zh)
MY (1) MY173812A (zh)
NO (1) NO2921489T3 (zh)
NZ (1) NZ707832A (zh)
PH (1) PH12015501056A1 (zh)
PL (1) PL2921489T3 (zh)
PT (1) PT2921489T (zh)
RU (1) RU2662157C2 (zh)
SG (1) SG11201503716RA (zh)
TW (1) TWI591064B (zh)
WO (1) WO2014077235A1 (zh)
ZA (1) ZA201503323B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 ２−ピリドン化合物を含有する医薬
JPWO2015174377A1 (ja) * 2014-05-13 2017-04-20 日産化学工業株式会社 ２−ピリドン化合物の製造方法
CN110548026B (zh) 2018-05-31 2022-01-14 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和k-atp通道阻断剂的药物组合及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
DK1169312T3 (da) 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
BRPI0712862A2 (pt) 2006-06-08 2012-12-18 Lilly Co Eli carboxamidas substituìdas
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
PE20090449A1 (es) * 2007-07-17 2009-04-18 Bristol Myers Squibb Co Agonistas de receptor acoplado a proteina g gpr119 de piridona
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
BR112012013195A2 (pt) * 2009-12-04 2016-08-09 Nissan Chemical Ind Ltd compostos de 2-piridona.
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd ２−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
MX2015005884A (es) 2015-12-09
IL238701A0 (en) 2015-06-30
HUE034557T2 (en) 2018-02-28
NO2921489T3 (zh) 2018-02-03
PH12015501056B1 (en) 2015-07-27
PH12015501056A1 (en) 2015-07-27
RU2662157C2 (ru) 2018-07-24
JP5963025B2 (ja) 2016-08-03
AU2013345930B2 (en) 2017-08-24
NZ707832A (en) 2019-03-29
JPWO2014077235A1 (ja) 2017-01-05
IL238701B (en) 2018-10-31
CN104768944A (zh) 2015-07-08
PL2921489T3 (pl) 2018-01-31
TWI591064B (zh) 2017-07-11
TW201434826A (zh) 2014-09-16
CN104768944B (zh) 2017-03-29
DK2921489T3 (en) 2017-10-16
SG11201503716RA (en) 2015-06-29
US9695148B2 (en) 2017-07-04
ES2641469T3 (es) 2017-11-10
EP2921489A4 (en) 2016-04-06
KR20150082301A (ko) 2015-07-15
BR112015010823A2 (pt) 2017-07-11
IN2015DN03869A (zh) 2015-10-02
CA2891406A1 (en) 2014-05-22
KR102160841B1 (ko) 2020-09-28
EP2921489B1 (en) 2017-09-06
CA2891406C (en) 2021-03-16
AU2013345930A1 (en) 2015-06-04
EP2921489A1 (en) 2015-09-23
MY173812A (en) 2020-02-24
RU2015122717A (ru) 2017-01-10
MX361479B (es) 2018-12-06
ZA201503323B (en) 2016-08-31
US20160289208A1 (en) 2016-10-06
PT2921489T (pt) 2017-12-01
WO2014077235A1 (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
HK1203498A1 (zh) 四氫吡唑並嘧啶化合物
HK1198761A1 (zh) 咪唑並吡咯啶酮化合物
EP2842955A4 (en) TRK-INHIBITING CONNECTION
EP2925129A4 (en) PRO-NEUROGENIC COMPOUNDS
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
HK1206726A1 (zh) 咪唑並三嗪酮化合物
GB201204985D0 (en) Compounds
GB201220843D0 (en) Compound
GB201204125D0 (en) Compounds
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
HK1206356A1 (zh) -取代的氰基吡唑化合物
HK1207856A1 (zh) -吡啶酮化合物
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201217310D0 (en) Compounds
HK1215569A1 (zh) 吡啶酮化合物
GB201216448D0 (en) Compound
GB201222716D0 (en) Compound
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211108